Metabolic aberrations and risk for prostate cancer

According to a newly published study of data from > 285,000 European males (the Metabolic Syndrome and Cancer Project), men with metabolic aberrations are at slightly less risk for a diagnosis of prostate cancer compared with men who have normal levels of metabolic factors … but their risk for prostate cancer-specific mortality is similar. … READ MORE …

15-year survival and related data after first-line brachytherapy

Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …

FDA approves use of enzalutamide in chemotherapy-naive mCRPC

This afternoon the U.S. Food & Drug Administration approved enzalutamide (Xtandi) as a treatment for patients with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) based on the results of the PREVAIL trial. … READ MORE …

ASCO, CCO issue new guidelines for management of metastatic prostate cancer

The American Society for Clinical Oncology (ASCO), in conjunction with Cancer Care Ontario (CCO), has just issued revised guidelines for the management of metastatic prostate cancer. … READ MORE …

How patients and others react to prostate cancer diagnosis and treatment

According to a media release issued earlier today by ZERO — The End of Prostate Cancer in conjunction with Ferring Pharmaceuticals Inc., “Prostate cancer impacts sex lives more than any other aspect of patients’ lives.” … READ MORE …

DCVAC/PCa and the VIABLE trial in men with mCRPC

It has been brought to our attention that a Czech company called Sotio, based in Prague, has recently initiated a randomized, multi-center, Phase III clinical trial (known as the VIABLE trial) of what appears to be a “second-generation” form of activated dendritic cell-based immunotherapy for the treatment of advanced prostate cancer. … READ MORE …

Addressing “sex vs. death” perceptions in prostate cancer treatment

The following is the full text of an article by Anne Katz, RN, PhD, who is a Clinical Nurse Specialist and AASECT-Certified Sexuality Counselor who blogs at ASCO Connection, where this post originally appeared. It is reproduced here with the kind permission of the American Society for Clinical Oncology. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,139 other followers